Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 39Terminated 8Unknown 3Withdrawn 2No longer available 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 5Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Recurrence 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Neoplasms 2Hematologic Diseases 2Congenital Abnormalities 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Melphalan 5Dexamethasone 4Bortezomib 3Arsenic Trioxide 3fludarabine phosphate 2Vorinostat 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Drug Therapy 2Busulfan 2Ascorbic Acid 2ogalvibart 1ethanolamine oleate 1daratumumab 1crexavibart 1carfilzomib 1Zoledronic Acid 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Thalidomide 1Tacrolimus 1Surveys and Questionnaires 1Sulfamethoxazole 1Sodium Chloride 1Simvastatin 1Saline Solution, Hypertonic 1Saline Solution 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Plasma Cell × Busulfan × Clear all
NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡